-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, many international experts have interpreted and shared the latest research progress in the field of hematology and their own diagnosis and treatment experience.
In this regard, [Yimaitong Hematology Department] organized an inventory and took you to review the insights and opinions of international experts from an international perspective.
Click "Related Article Title" to read the relevant original text.
Dr.
Mark A.
Schroeder, Associate Professor of Oncology, Washington University School of Medicine in St.
Louis, selected 3 articles about graft-versus-host disease (GVHD) related research progress reported at the 2020 American Society of Hematology Annual Meeting (ASH 2020).
Parsing.
For more details, please click: International Perspective | Professor Mark A.
Schroeder analyzes the three major research progress of GVHD As more and more patients with chronic lymphocytic leukemia (CLL) begin to receive high-efficiency targeted drugs and new combination treatments, explore disease assessment and guidance Accurate indicators of treatment decisions are becoming more and more important.
Professor Danielle Brander of the Department of Medicine of Duke University reviewed the clinical trial data and discussed the role of MRD assessment in the management of CLL.
For details, please click: International Perspective | What role does MRD negative play in the clinical management of CLL? With the introduction of various immunotherapies, the treatment model for multiple myeloma (MM) has developed rapidly.
Professor Shaji Kumar from the Mayo Clinic in the United States reviewed the new methods of MM immunotherapy.
For details, please poke: International Perspective | Professor Shaji Kumar's interpretation of a new method of multiple myeloma immunotherapy.
The treatment of multiple myeloma (MM) is developing rapidly.
Professor Shaji Kumar from the Mayo Clinic in the United States reviewed the latest developments in MM, including the management of smoking MM patients and the treatment options for high-risk MM patients.
For details, please stamp: International Perspective | Professor Shaji Kumar's interpretation of the progress of stratified treatment of multiple myeloma.
For patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), the main treatment goal is to achieve complete remission (CR).
The best treatment goal is to achieve minimal residual disease (MRD) negative.
Professor David Marks from the University of Bristol in the United Kingdom shared the experience of using Blinatumomab and Inotuzumab ozogamicin in patients with R/R ALL.
For details, please click: International Perspective | The application of belintoumab and Inotuzumab Ozogamicin in patients with relapsed/refractory ALL For neoplastic diseases, precise diagnosis and precise stratification are particularly important.
Professor Rami S.
Komrokji from the Lee Moffett Cancer Research Center in the United States shared the experience and challenges of the treatment of high-risk and low-risk MDS.
For more details, please click: International Perspective | Treatment Challenges and New Strategies for Myelodysplastic Syndrome In recent years, research on chimeric antigen receptor T cells (CAR-T) has exploded globally, and its progress has been widely received by doctors and patients attention.
Professor Natalie S.
Callander, Director of the Myeloma Clinical Program at the University of Wisconsin in the United States, expressed her views on the research progress and future development of CAR-T therapy targeting BCMA in the field of multiple myeloma.
For details, please poke: International Perspective | The treatment prospects of CAR-T targeting BCMA in myeloma At the 2019 American Hematology Annual Conference (ASH) satellite meeting, Professor Steven M.
Horwitz of the Memorial Sloan Kettering Cancer Center in New York targeted How to best manage patients with peripheral T-cell lymphoma (PTCL) was shared.
For more details, please stamp: International Perspective | Professor Steven M.
Horwitz talks about common problems in the management of peripheral T-cell lymphoma stamp "Read the original text", we make progress together
In this regard, [Yimaitong Hematology Department] organized an inventory and took you to review the insights and opinions of international experts from an international perspective.
Click "Related Article Title" to read the relevant original text.
Dr.
Mark A.
Schroeder, Associate Professor of Oncology, Washington University School of Medicine in St.
Louis, selected 3 articles about graft-versus-host disease (GVHD) related research progress reported at the 2020 American Society of Hematology Annual Meeting (ASH 2020).
Parsing.
For more details, please click: International Perspective | Professor Mark A.
Schroeder analyzes the three major research progress of GVHD As more and more patients with chronic lymphocytic leukemia (CLL) begin to receive high-efficiency targeted drugs and new combination treatments, explore disease assessment and guidance Accurate indicators of treatment decisions are becoming more and more important.
Professor Danielle Brander of the Department of Medicine of Duke University reviewed the clinical trial data and discussed the role of MRD assessment in the management of CLL.
For details, please click: International Perspective | What role does MRD negative play in the clinical management of CLL? With the introduction of various immunotherapies, the treatment model for multiple myeloma (MM) has developed rapidly.
Professor Shaji Kumar from the Mayo Clinic in the United States reviewed the new methods of MM immunotherapy.
For details, please poke: International Perspective | Professor Shaji Kumar's interpretation of a new method of multiple myeloma immunotherapy.
The treatment of multiple myeloma (MM) is developing rapidly.
Professor Shaji Kumar from the Mayo Clinic in the United States reviewed the latest developments in MM, including the management of smoking MM patients and the treatment options for high-risk MM patients.
For details, please stamp: International Perspective | Professor Shaji Kumar's interpretation of the progress of stratified treatment of multiple myeloma.
For patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), the main treatment goal is to achieve complete remission (CR).
The best treatment goal is to achieve minimal residual disease (MRD) negative.
Professor David Marks from the University of Bristol in the United Kingdom shared the experience of using Blinatumomab and Inotuzumab ozogamicin in patients with R/R ALL.
For details, please click: International Perspective | The application of belintoumab and Inotuzumab Ozogamicin in patients with relapsed/refractory ALL For neoplastic diseases, precise diagnosis and precise stratification are particularly important.
Professor Rami S.
Komrokji from the Lee Moffett Cancer Research Center in the United States shared the experience and challenges of the treatment of high-risk and low-risk MDS.
For more details, please click: International Perspective | Treatment Challenges and New Strategies for Myelodysplastic Syndrome In recent years, research on chimeric antigen receptor T cells (CAR-T) has exploded globally, and its progress has been widely received by doctors and patients attention.
Professor Natalie S.
Callander, Director of the Myeloma Clinical Program at the University of Wisconsin in the United States, expressed her views on the research progress and future development of CAR-T therapy targeting BCMA in the field of multiple myeloma.
For details, please poke: International Perspective | The treatment prospects of CAR-T targeting BCMA in myeloma At the 2019 American Hematology Annual Conference (ASH) satellite meeting, Professor Steven M.
Horwitz of the Memorial Sloan Kettering Cancer Center in New York targeted How to best manage patients with peripheral T-cell lymphoma (PTCL) was shared.
For more details, please stamp: International Perspective | Professor Steven M.
Horwitz talks about common problems in the management of peripheral T-cell lymphoma stamp "Read the original text", we make progress together
